Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Read for yourself the September 15th news release, Not true at all,...
"In other newly conducted lab testing at the RBL, Brilacidin was shown to inhibit SARS-CoV-2 in a human intestinal epithelial cell line and in primary fibroblast cells obtained from human donors. The Company has been informed by the RBL that it is nearing completion of its in vitro testing of Brilacidin against SARS-CoV-2 and will be submitting findings for peer-review publication. The publication will be solely focused on Brilacidin, with a pre-print made available."
RBL preprint & peer review publication, when???
Didn't the RBL inform Leo the RBL Brilacidin peer review was going to be published in September.... September ends on Wednesday!
What's the update... I took a mental vacation from these blogs expecting the snails progress and frustration! Not saying we can't all haul in huge profits for our investment someday, but I worry the opportunity is slipping away????
Today's information has been picked up by Reuters. The release has been reduced to 2 bullet points. Significantly minimizes the importance of the PR, IMO
BRIEF-Innovation Reports Data From Lab Supporting Brilacidin As Potential Treatment For SARS-CoV-2
BY Reuters
— 9:17 AM ET 09/15/2020
Sept 15 (Reuters) - Gilead Sciences Inc (GILD):
* INNOVATION PHARMACEUTICALS (IPIX) - REPORTS ADDITIONAL DATA FROM LAB SUPPORTING BRILACIDIN AS POTENTIAL TREATMENT FOR SARS-COV-2
* INNOVATION PHARMACEUTICALS INC (IPIX) - LABORATORY TESTING OF BRILACIDIN FOR COVID-19 IN COMBINATION WITH REMDESIVIR REDUCES VIRAL LOAD BY NEARLY 100% Source text for Eikon: Further company coverage:
Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
FirstWord Pharma reported today.... their link... "Dr-William-F-DeGrado-a-Discoverer-of-Brilacidin-Joins-Innovation-Pharmaceuticals-as-Scientific-Advisor"
BTW, Firstword Pharma is a very popular source for Healthcare Industry News ... Great exposure for IPIX and Brilacidin!
http://www.globenewswire.com/news-release/2020/08/26/2084130/0/en/Dr-William-F-DeGrado-a-Discoverer-of-Brilacidin-Joins-Innovation-Pharmaceuticals-as-Scientific-Advisor.html
I would say Dr. DeGrado is unbelievably well connected, look at all the collaborations he's has been part of.... these connections are GOLD for getting the funding and attention Brilacidin now deserves!
Dr. William DeGrado "Antibiotic Artisan" Great Read, written in 2011.
"The biotech industry creates new drugs by making tweaks to natural proteins. University of Pennsylvania chemist William DeGrado is more of an artist than a tweaker."
https://www.forbes.com/forbes/2011/0214/technology-william-degrado-chemistry-biotech-antibiotic-artisan.html#3820e0b7bdce
Physician's Weekly.. Remdesivir Disappoints As Covid-19 Therapy in Phase III Trial, Aug 25, 2020
A lot more information about the results in the link below if you're interested.
IMO, the bottom line regarding the less than stellar Remdesivir COVID-19 Trial is best summed up in the report as.... "Improvement seen with 5-day course, but clinical benefit uncertain" NOT the Gold Standard!!!
Make way for BRILACIDIN to the rescue!!!
https://www.physiciansweekly.com/remdesivir-disappoints-as-covid-19-therapy-in-phase-iii-trial/
JAMA- Remdesivir Disappoints in COVID-19 Study in research published on Friday (8/21) in JAMA.
"A new study is raising fresh questions about the efficacy of Gilead Sciences Inc's anti-viral medication remdesivir in COVID-19 patients."
"A randomized, controlled trial of remdesivir in 584 moderately ill COVID-19 patients hospitalized with pneumonia yielded disappointing results in research published on Friday in JAMA. Compared to standard care without remdesivir, a 10-day course of the drug did not show a statistically significant effect on disease course at 11 days after treatment started, the study found."
"A five-day remdesivir course did make a statistically significant difference, but one so small that the researchers are not sure it really matters."
"Several other gold-standard trials are still underway, but as of now important questions remain regarding remdesivir's efficacy, Erin McCreary and Derek Angus of the University of Pittsburgh wrote in an editorial published alongside the study. They raised questions about whether some patients get more benefit from remdesivir than others and whether it matters if patients receive remdesivir and steroids together."
IMO - You can drive a proverbial "Brilacidin Mack Truck" thru the Unprecedented COVID-19 Opportunity based on Brilacidin's earlier released research results as compared with Remdesivir's similar lack luster trial results .... Time to Seize the Moment Innovation!!!! Time for some very serious Federal Cash Infusion and attention for Brilacidin!
https://www.newsmax.com/t/newsmax/article/983357/18
Leo, I'm at the end of my rope with you. The gloves are off! Locust walk has done NOTHING in the last year for IPIX, a complete waste of time and money. Stock price is still pathetic even with the unbelievable opportunity (I'm not celebrating this Pandemic) for B. What a huge gift opportunity for B, free trials, Non- Bias RBL analysis, HUGE Demand, early analysis much better than Remdesivir's in similar trials and Leo and company still can't get a lick accomplished YTD to drive the price up. Nobody could've asked for or expected a more perfect storm to launch a drug like Brilacidan with the gift conditions and circumstances he's been given! What happened to the RBL Grant(s)???
As a Long since 2013.... I'm at the end of my rope with Leo, IPIX, CTIX the whole sad situation, what a waste of time!!!!! I hope I'm wrong, boy to I hope I'm wrong but I have serious doubts.... POOR communication and marginal partnerships at best, more like a joke of Partnerships thus far.
Genentech’s lead IBD drug's Phase III readouts spell disaster https://endpts.com/phase-iii-readouts-spell-disaster-for-genentechs-lead-ibd-drug/
"Roche had big plans for etrolizumab. Eyeing a hyper-competitive IBD and Crohn’s market where they have not historically been a player, the company rolled out 8 different Phase III trials, testing the antibody for two different uses across a range of different patient groups."
"On Monday, Roche released results for 4 of those studies, and they mark a decided setback for both the Swiss pharma and their biotech sub Genentech, potentially spelling an end to a drug they put over half-a-decade and millions of dollars behind."
Levi Garraway
“We are disappointed with these results, because we know that people with ulcerative colitis need new treatment options,” CMO Levi Garraway said in a statement.
"Genentech did not release the topline data, but said they will do so at future medical conferences. The safety results were consistent with previous studies, the company said."
"The results won’t end the late-stage IBD program, even as it sets it back considerably. In addition to open-label expansion studies, the company is still running a pair of Phase III trials in Crohn’s disease."
"Behind etrolizumab, Genentech has one other mid-stage asset for inflammatory diseases: An IL-22 fusion protein now in Phase II for IBD. By contrast, etrolizumab works as an integrin inhibitor similar to Takeda’s Entyvio."
I'm sorry to hear about the challenges your family has faced. Praying for your family. The potential of Kevetrin is what originally drew me to invest in CTIX/IPIX.
Dilution of AUPH Stock at loyal stockers holders expense, not a brilliant strategy. :(
I meant but wasn't clear ... the term grease the skids to mean "squeaky wheel get the grease" or more applicable to IPIX "the squeaky wheel gets the GRANTS." Grease by Dissemination of the great RBL data and possibly gets the help it needs to fund the trials, gets the necessary assistance for manufacturing, etc... Get potentailly the best drug that currently exists to combat COVID-19 to the world.
Leo and others needs to grease the skids with anybody on The White House COVID-19 Committee .... this would get there attention for a potential HUGE breakthrough.... Tell them did you hear, Innovation's Brilacidin is superior to Remdesivir's similar trial results? Yeah that's right... your big hope drug is less potent, less effective and more toxic!!!
A recent RBL trial reported these results:
"In the RBL assay (which included Brilacidin pre-incubated with virus), Brilacidin exhibited approximately 90 percent inhibition against SARS-CoV-2 at a concentration similar to that of Remdesivir™, which again reported 50 percent inhibition of the coronavirus."
From the July 20, 2020 PR:
"To put the new RBL testing results in additional context, an article published in Nature showed that Gilead Sciences’ Remdesivir™ achieved 50 percent inhibition against SARS-CoV-2, in a time-of-addition experiment, at a concentration of 3.7 µM in Vero (animal) cells. Remdesivir™ has received attention worldwide as one of the few effective therapies for treating COVID-19, gaining varying levels of authorized use in the U.S., E.U., U.K., India, Singapore, Japan, and Australia.
In the RBL assay (which included Brilacidin pre-incubated with virus), Brilacidin exhibited approximately 90 percent inhibition against SARS-CoV-2 at a concentration similar to that of Remdesivir™, which again reported 50 percent inhibition of the coronavirus. The Brilacidin inhibition assay was tested in a human lung epithelial cell line, with Remdesivir™ tested in Vero cells. The RBL data also supports Brilacidin showing an ability to inhibit viral entry into cells, a highly desirable mechanism of action as it is the first step in the infection process enabling viruses to be targeted outside the cell, whereas Remdesivir™ impacts viral replication only after the host cell has been infected.
The Company believes that Brilacidin and Remdesivir™, tested in combination, may generate even greater antiviral potency. RBL staff and the Company are considering conducting in vitro experiments to assess such potential synergistic effects. No assurances are made or implied that such combination studies will be conducted."
You're right, crying over pennies while they trip over potential dollars, being long means staying long. The potential Stock Appreciation was made even more realistic by the last few PR's with COVID-19 human lung cell data extracted by the INDEPENDENT Laboratories! The data wasn't even a base hit, it was a Grand Slam vs. Gilead's "widely praised" Remdesivir studies.
Bralacidan having already been previously studied in 480 human patients has already proven it's safe as well, a big advantage over the other BP "potentials" you hear about.
LR - good points. Here is some info regarding a time of drug based approach. Additional data from future PRs will help to clarify.
Abstract
Insight into the mode of action of newly discovered antiviral agents is now almost a prerequisite for clinical development. This protocol describes a method that provides information on the target of inhibitors of the human immunodeficiency virus (HIV); it can also be adapted to other viruses. The results from this experiment are available within 2 d. This time-based approach determines how long the addition of a compound can be postponed before losing its antiviral activity in cell culture. The target of an antiviral compound can be identified by comparing its relative position in the time scale to that of reference drugs. Therefore, it is more precise than, for example, in the case of HIV, a determination of pre- or postintegrational mode of action, and combines in one routine different assays for studying mechanisms of action.
https://www.nature.com/articles/nprot.2011.330?message-global=remove
There's already a Big Pharma COVID-19 consortium put together to aid development of manufacturing of a small biotech and unique therapy like Brilacidin that was just found superior the the "Mighty" Remdesivir in their similar trial on efficacy and potency. I know Pfizer publically announced such support a month ago and they are just one member of the consortium.
Karen today's news was Great in content and results but failed miserably in getting out to the major news outlets.... this can't continue if we want to see major stock appreciation. To be honest Global News Wire is a joke! We need bigger and more respected dissemination, Reuter's, Wall Street Journal, Cramer, AP, Twitter, White House Updates on COVID-19 Therapeutics, etc...
The recent Brilacidin RBL data shows far superior clinical results to Remdesivir's in similar clinical trails. The scientific and political community should not ignore the results if we help disseminate the last few PR's. The General public will not be to happy to see Brilacidin's superior results to a Big Pharma drug (Remdesivir) go ignored and not supported when we are talking about a Pandemic here!
Call to Action:
Let's all move beyond wishful thinking and start copy and pasting the latest PR to all news channels, social media, Facebook, Twitter, LinkedIn, etc... as often as we can starting NOW!!!
FDA cites "Limitations of Remdesivir in treating Covid19 patients:"
FDA NEWS RELEASE
Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use
Share
Tweet
Linkedin
Email
Print
For Immediate Release:
June 15, 2020
Español
Today, the U.S. Food and Drug Administration is warning health care providers about a newly discovered potential drug interaction related to the investigational antiviral drug remdesivir, which has received emergency use authorization for the treatment of hospitalized COVID-19 patients with severe disease.
Based on a recently completed non-clinical laboratory study, the FDA is revising the fact sheet for health care providers that accompanies the drug to state that co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended as it may result in reduced antiviral activity of remdesivir. The agency is not aware of instances of this reduced activity occurring in the clinical setting but is continuing to evaluate all data related to remdesivir.
In addition, the FDA revised the fact sheet for health care providers to clarify dosing and administration recommendations and to provide additional safety data and supporting data from clinical trials conducted by both the National Institutes of Health and the drug sponsor, Gilead Sciences Inc. The fact sheet for patients and caregivers was also updated to include additional information about possible allergic reactions and to alert patients to tell their healthcare providers if they are taking chloroquine phosphate or hydroxychloroquine sulfate.
“Over the course of this unprecedented pandemic, the FDA has issued emergency use authorizations for a variety of medical products after evaluating the available scientific evidence and carefully balancing any known or potential risks against the benefits of making these products available during the current public health emergency. We understand that, as we learn more about these products, changes may be necessary based on new data – such as today’s updates for health care providers about a potential drug interaction and other important information about using remdesivir to treat COVID-19 patients,” said Patrizia Cavazzoni, M.D., acting director of the FDA’s Center for Drug Evaluation and Research. “As we have done throughout the pandemic, the FDA continues to evaluate all of the emergency use authorizations issued and their related materials and will continue to make changes as appropriate based on emerging science and data.”
Following an evaluation of the emergency use authorization criteria and the scientific evidence available, the FDA issued an emergency use authorization (EUA) in May 2020 allowing for remdesivir to be distributed in the U.S. and to be administered intravenously by health care providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in adults and pediatric patients hospitalized with severe disease. The safety and efficacy of remdesivir for the treatment of COVID-19 continue to be evaluated, and preliminary clinical trial results have shown that on average, patients treated with remdesivir had more rapid time to recovery.
The EUA requires that fact sheets about using remdesivir in treating COVID-19 be made available to health care providers and to patients and caregivers. These fact sheets include information on possible side effects such as: increased levels of liver enzymes, which may be a sign of inflammation or damage to cells in the liver; and allergic reactions, which may include low blood pressure, high heart rate, low heart rate, shortness of breath, wheezing, angioedema (for example, lip or tongue swelling), difficulty swallowing, rash, nausea, vomiting, sweating, shivering and respiratory distress.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
###
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-warns-newly-discovered-potential-drug-interaction-may-reduce
There is still insufficient data for the NIH to recommend either for or against the use of remdesivir for the treatment of patients with mild or moderate COVID-19, the agency said.
NIH updates Remdesivir treatment guidelines updated 7/20/2020.
"The National Institutes of Health has updated its treatment guidelines for Gilead's remdesivir, the antiviral drug that has received emergency authorization from the FDA to treat COVID-19.
The agency said July 17 that in situations where supplies of remdesivir are limited, it recommends prioritizing remdesivir for use in hospitalized patients who require supplemental oxygen but aren't mechanically ventilated.
The NIH said the update was made because of a clinical trial that showed patients with severe COVID-19 who received remdeivir had a shorter time to recovery than those who received the placebo, but that the drug has the clearest benefit in hospitalized patients who require supplemental oxygen but not ventilation.
The agency said there is uncertainty as to whether remdesivir has an impact on the course of COVID-19 disease in patients who are on mechanical ventilation.
The NIH also said that there is insufficient data on the optimal duration of remdesiivr treatment for patients who haven't shown substantial clinical improvement after five days, so some providers may consider extending the total remdesivir treatment duration to up to 10 days.
There is still insufficient data for the NIH to recommend either for or against the use of remdesivir for the treatment of patients with mild or moderate COVID-19, the agency said.
https://www.beckershospitalreview.com/pharmacy/nih-updates-remdesivir-treatment-guidelines.html
The NIH said it expects to release additional updates to remdesivir recommendations soon.
Read the agency's full remdesivir guidance here."
I bought more thanks pal. $$$$)
Agree with your post 100% !!! Leo should concentrate on these priorities:
1) Securing study drug
2) Securing a Big League PR Firm/ Transaction Firm with Brilacidin's impressive assets already discussed in today's PR.
Global News Wire isn't cutting it anymore, need air time on bigger well established news outlets!!! There's something wrong when at 11:00 AM we see only a .06 cent bump on this PR!!!!????
Happy to get to this point out of the abyss .... better lucky (right drug at the right time, timing is everything) than good most of the time. Credit goes to Leo in keeping IPIX viable over all these years on a shoe string budget, hopefully that all changes with this PR!
Pfizer and many other BP and the Go't already publicly offered to assist in manufacturing, testing, etc... for small Biotech who may have caught Lightening in a Bottle .... BRILACIDIN should get FAST TRACKED immediately..
If this PR doesn't get major attention (Included in a White House Update) it's as good or better than a GRANT Approval, nothing will. Brilacidin destroys Remdesivir in Efficacy, Potency and Novel Mechanism of Action.
Disseminate, Disseminate, Disseminate todays Unbelievable PR...The best way to cut the RED tape!!!!
If all us longs posted todays PR, think how widespread the news would spread.
Take Action: Copy and Paste throughout the day when you get a chance on social media.
Go Leo.... Let Gilead pay for the trial.... Brilacidin is far more effective clinically and a much better MOA than Remdesivir and any other option. Kills before not after the fact.
Absolute deal at .32 .... a week or two from now IMO. If you're selling now your a day trader, your going to get a big surprise very soon!
IMO, when Brilacidin is approved for an NIH/Federal Grant (s) for in human COVID-19 trials, IPIX stock will benefit greatly from all the previous very positive public PR's on Brilacidin's activity, safety and novel Mechanism of Action (MOA) that is largely unknown to the general public! New investors will jump on board in droves!
* For the stock to really soar in the short term one of the following needs to take place IMO:
Leo will need to uplist on the big board as soon as IPIX meets the criteria. and/or
Leo announces a big deal partnership in the Hundred of Millions $$$ with heavy milestone payouts, again in the Tens of Millions.
Leo announces a MEGA Buy Out in the $10 - 20 Billion range, maybe much higher with all the possible Brilacidin indications and with a potential block buster in itself, Kevetrin!!!
Go IPIX!!!!
Brilacidin 97% reduction vs. the control arm is statistically EXTREMELY Significant and a game changer! Even Better!!! ;)
Sorry for the duplicate post! Independant RBL trial results, 97% reduction, a P-Value p< 0.0001 expect to hear IMO GRANT APPROVED!
"Most recently, Brilacidin exhibited a Statistically Significant (p<0.0001) and potent inhibitory effect on SARS-CoV-2 in a human lung epithelial cell line, reducing viral load by up to 97% compared to control."
WHAT does that mean???? Answer..... A P-Value of (p< 0.0001) Means that Brilacidin's 97% reduction of viral load compared to the control arm in Human Lung epithelial cells conducted by the INDEPENDENT RBL Trial ... the expected results being PURELY BY CHANCE are LESS THAN
1 in 1000 times, in other words if the same trial was conducted 1000 times, less than 0.0001% of the time the trial would have the same result by pure chance alone!!! A (p< 0.0001) clinically speaking is proof beyond a reasonable doubt, look it up!
Brilacidin exhibited a Statistically Significant (p<0.0001) and potent inhibitory effect on SARS-CoV-2 in Human Lung Epithelial Cell Line, reducing viral load by up to 97% compared to control = IMO a GRANT Approval $ slam dunk and expect the Stock Price $$$$$ to soar!
Longs be patient, it will be Life Changing!
Smaller p-values = stronger evidence!!!!
Independant RBL trial results, 97% reduction, a P-Value p< 0.0001 expect to hear IMO GRANT APPROVED!
"Most recently, Brilacidin exhibited a Statistically Significant (p<0.0001) and potent inhibitory effect on SARS-CoV-2 in a human lung epithelial cell line, reducing viral load by up to 97% compared to control."
WHAT does that mean???? Answer..... A P-Value of (p< 0.0001) Means that Brilacidin's 97% reduction of viral load compared to the control arm in Human Lung epithelial cells conducted by the INDEPENDENT RBL Trial ... the expected results being PURELY BY CHANCE are LESS THAN
1 in 1000 times, in other words if the same trial was conducted 1000 times, less than 0.0001% of the time the trial would have the same result by pure chance alone!!! A (p< 0.0001) clinically speaking is proof beyond a reasonable doubt, look it up!
Brilacidin exhibited a Statistically Significant (p<0.0001) and potent inhibitory effect on SARS-CoV-2 in Human Lung Epithelial Cell Line, reducing viral load by up to 97% compared to control = IMO a GRANT Approval $ slam dunk and expect the Stock Price $$$$$ to soar!
Longs be patient, it will be Life Changing!
Smaller p-values = stronger evidence!!!!
Sad I have to explain: Brilacidin hasn't failed to deliver in clinical trials PERIOD!
Lack of proper funding, leadership, promotion and other reasons (MAKO) is another story. Leo would have to royally screw it up now not to deliver with non dilutive grant money to human trials in this COVID-19 time and place.
"The stock market is a device for transferring money from the impatient to the patient." - Warren Buffett
Brilacidin FACTS thus far.. Brilacidin has never failed to deliver in clinical trials: 97% efficacy against COVID-19 Lung tissue, Amazing P-Value 0.0001, 99.99% Statistically Significant, meaning the trial result outcomes DID NOT occur randomly or by chance! Another major takeaway, Brilacidin is non toxic to lung tissues!!! IMO Brilacidin is a no brainer for a grant for human trials. These impressive results have not been duplicated. The demand for a therapy (ies) that delivers is immense, great for mankind and IMO huge rewards will follow for patient investors!!! Below is a excerpt from the latest PR that should help steady your nerves... lol
"Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of 8) for other clinical indications, providing an established safety and efficacy database on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. Ongoing laboratory testing conducted at a U.S. Regional Biocontainment Laboratory (RBL), and at a Public Health Research Institute (PHRI), supports Brilacidin’s antiviral ability to safely inhibit SARS-CoV-2 in both human and animal cell lines."
"A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Additional pre-clinical and clinical data support Brilacidin’s potential to inhibit IL-6, IL-1ß, TNF-a and other pro-inflammatory cytokines and chemokines, which have been identified as central drivers in the worsening prognoses of hospitalized COVID-19 patients."
"Brilacidin’s robust antimicrobial properties might also help to fight secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. These data collectively support Brilacidin as a unique 3 in 1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—anti-COVID-19 therapeutic candidate."
Wait for the Grant Approval news... be patient.
TWEET, etc... the recent excellent press release to help the cause instead of wishful thinking! :)
We've come a LONG way since January this year and it' just the beginning, strap in and enjoy the ride. Stay positive, and Stay Long.
If If If ..... Brilacidin's efficacy and safety and P value results just continue going forward in human trials, we all win $$$!!!
IPIX stock value will pop with a pending Federal Grant approval and some level of good media attention, then an unbelievable stock jump on positive human trial results + real media attention to quickly follow = FAST Approval for use, FAST up-listing and/or a Big Pharma frenzy for a buy out.
Most importantly Great for World Health, Great for the World Economy and Unbelievable for Investors!
We don't disagree. Just emphasizing IMO that IPIX stock value will not be as predictable as your past experience might dictate in ordinary times.... more like an explosion of stock value based on Urgency, Great Results and Poor outcomes and little hope thus far from other attempts in the industry.
IPIX is going to catch lightening in a bottle IMO this year.
Sorry, don't agree.... IPIX is going to explode this year... there's nothing typical about the potential of Brilacidin and the efficacy shown YTD and this Pandemic.
IMO there's No Way we don't get the Brilacidin Grant APPROVED for Human Trials this week.
We heard back on 6/11 that the grant was going to be jointly submitted with RBL recommendations by the next day or end of week, same difference. IMO we will easily get the approval based on Brilacidin's incrediabley impressive clinical results in the human lung tissue 97% & 95% Efficacy against SARS-CoV-2 based on two therapeutic concentration levels where Brilacidin showed a STATISTICALLY SIGNIFICANT P Value of < 0.0001.... meaning there was no chance that those impressive results were random!
ADD: Brilacidin is non-cytotoxic in these trials in the lung cell line. All combined, there are no better results than that going into Human trials. Highly credible non-biased RBL trials, near 100% efficacy with a P < 0.0001 and safe in the human lung cell line.
ADD: There is still an urgency without vaccines and new case reporting on the rise.
Don't know were this is heading but I'm glad to have my shares, staying for an extremely generous buyout or significant SP of greater than $25 or more/share. Who knows, it could go above $100 per share if certain key variables/timing fall into place.
Like minded investors think: With HUGE Rewards (Life Changeing) there are Risks but those risks should be calculated risks (DD) not just wishful thinking. With each of the last few PR's the Risks have lessoned greatly while the Potential for real Rewards have gone up exponentially, it really hasn't reflected in today's stock price due to extreme lack of public exposure, YET. IMO
Really enjoying the ride ... finally! Expecting not guaranteeing unbelievable results based on the Clinical Data already reached, not Hype!
Leo could assemble a team. At the same time he could be getting amazing offers (In $ Billions) from BP vying to buy the assets.... for stepping up and solving this World Wide Pandemic.
Let's all hope that the mainstream media (No offense Global News Wire) pick up on the amazing Brilacidin PR that was just released and it goes out to the world as the next GREATEST Promising agent against COVID-19, based on the science and data results, not BP hype.
Buy Out like Pharmacyclics not going to be another Regeneron.
IMO There's no way Leo and his tiny inexperienced crew has the horsepower to follow the Regeneron model. Try the Pharmacyclics model of having 3-4 BP suiters outbidding each other for the rights to Brilacidin and Kevetrin once human trials prove to be a home run with COVID-19... It will be HUGE!!!!
Extreme example but it happed: 2015, AbbVie bought Pharmacyclics (half the rights of Imbruvica for $261.00 a share) after heavy bidding by J&J, Pfizer and winner AbbVie .... J&J already owned the rights to the other half of Imbruvica/Imatinib after paying Pharmacyclics almost 1 Billion dollars and funding double digit trials that were under way. I know, I was there at start up through the Buyout.
That's how you do it LEO!!!